頁籤選單縮合
題名 | 特發性肺纖維化標靶藥品治療=Targeted Therapy for the Treatment of Idiopathic Pulmonary Fibrosis |
---|---|
作者 | 施雅分; 廖淑貞; 簡素玉; | 書刊名 | 藥學雜誌 |
卷期 | 35:1=138 2019.03[民108.03] |
頁次 | 頁9-13 |
分類號 | 418.31 |
關鍵詞 | 特發性肺纖維化; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidone; |
語文 | 中文(Chinese) |
中文摘要 | 特發性肺纖維化是一種慢性進展性的疾病,特徵是肺部纖維化,進而造成肺功能 惡化。衛生福利部核准 nintedanib 及 pirfenidone 兩種標靶藥品,用來治療特發性肺纖 維化病人,可明顯減緩用力肺活量 (Forced vital capacity, FVC) 的下降速度。不過,沒 有確切的證據證明這兩種藥品何者對於特發性肺纖維化病人的療效較佳。此外,兩者 副作用略有不同,nintedanib 在腹瀉和肝功能異常較為常見,而 pirfenidone 在胃腸道 和皮膚相關事件較為常見,因此,需依病人的個別性質進行選擇適當的藥品。 |
英文摘要 | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease, characterized by fibrosis and worsening lung function. The Taiwan Ministry of Health and Welfare approved both nintedanib and pirfenidone for the treatment of IPF. Evidence for changes in forced vital capacity (FVC) showed a significantly slower decline in patients treated with nintedanib or pirfenidone. There is no clear evidence regarding which drug is superior. In addition, the two drugs have slightly different side-effect profiles. Diarrhea and liver dysfunction were more common in the nintedanib group, whereas gastrointestinal and skin-related events were more common in the pirfenidone group. Therefore, the choice between nintedanib and pirfenidone for IPF must be individualized. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。